Opaleye Management Inc. purchased a new stake in Quanterix Corp (NASDAQ:QTRX) in the fourth quarter, HoldingsChannel reports. The fund purchased 65,000 shares of the company’s stock, valued at approximately $1,395,000. Quanterix accounts for 0.4% of Opaleye Management Inc.’s portfolio, making the stock its 29th largest holding.
Separately, Jennison Associates LLC bought a new stake in Quanterix in the 4th quarter valued at $6,353,000. 8.95% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have weighed in on QTRX shares. BTIG Research started coverage on shares of Quanterix in a report on Tuesday, January 2nd. They issued a “buy” rating and a $26.00 price target for the company. Leerink Swann assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 price objective for the company. Cowen assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “overweight” rating for the company.
Quanterix Corp (NASDAQ QTRX) opened at $23.39 on Tuesday. Quanterix Corp has a 1-year low of $15.56 and a 1-year high of $24.81.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/02/20/65000-shares-in-quanterix-corp-qtrx-purchased-by-opaleye-management-inc.html.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Corp (NASDAQ:QTRX).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.